Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT01580241
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer
Sponsor: University of Oklahoma
View on ClinicalTrials.gov
Summary
The investigators believe DCAMKL-1 is a stem cell tumor marker and is elevated in patients with pancreatic cancer. The investigators would like to analyze its expression pre and post treatment, to gauge the correlation between current pancreatic cancer therapies and the expression of DCAMKL-1
Official title: Expression Patterns of Stem Cell Marker Doublecortin and CaM Kinase-Like-1 (DCAMKL-1) in Human Pancreatic Adenocarcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2010-10
Completion Date
2027-12
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Locations (1)
Stephensen Cancer Center
Oklahoma City, Oklahoma, United States